Locally advanced breast cancer: the outcome of primary polychemotherapy based on infusional 5 fluorouracil

Over a 5-year period, 75 patients with locally advanced breast cancer prese nting to the Edinburgh Breast Unit were managed with a policy of infusional primary chemotherapy. For 65 patients, the regimens comprised infusional 5 fluorouracil with anthracycline and/or either cyclophosphamide or cisplati num (AcF, CAF or ECF) whilst 10 older patients had CMF-inf. The overall act ivity and tolerability for the regimens was good with a 76% objective respo nse rate including 15% clinical complete responses. Surgery was possible in 64% and pathological complete responses confirmed in 7 (9.3%). Median dise ase free survival (DFS) is 5.23 years. Factors predicting for DFS or Overal l Survival (OS) were assessed in this small group and ER positive patients did better than ER negative although there was surprisingly no negative DFS or OS association with inflammatory disease or advancing age. We found a p aradoxical interaction with use of post-chemotherapy tamoxifen which was si gnificantly associated with poorer DFS and OS overall and in the ER negativ e subgroups. (C) 1999 Harcourt Publishers Ltd.